Metabolomic prediction of endometrial cancer
- 352 Downloads
Endometrial cancer (EC) is associated with metabolic disturbances including obesity, diabetes and metabolic syndrome. Identifying metabolite biomarkers for EC detection has a crucial role in reducing morbidity and mortality.
To determine whether metabolomic based biomarkers can detect EC overall and early-stage EC.
We performed NMR and mass spectrometry based metabolomic analyses of serum in EC cases versus controls. A total of 46 early-stage (FIGO stages I–II) and 10 late-stage (FIGO stages III–IV) EC cases constituted the study group. A total of 60 unaffected control samples were used. Patients and controls were divided randomly into a discovery group (n = 69) and an independent validation group (n = 47). Predictive algorithms based on biomarkers and demographic characteristics were generated using logistic regression analysis.
A total of 181 metabolites were evaluated. Extensive changes in metabolite levels were noted in the EC versus the control group. The combination of C14:2, phosphatidylcholine with acyl-alkyl residue sum C38:1 (PCae C38:1) and 3-hydroxybutyric acid had an area under the receiver operating characteristics curve (AUC) (95% CI) = 0.826 (0.706–0.946) and a sensitivity = 82.6%, and specificity = 70.8% for EC overall. For early EC prediction: BMI, C14:2 and PC ae C40:1 had an AUC (95% CI) = 0.819 (0.689–0.95) and a sensitivity = 72.2% and specificity = 79.2% in the validation group.
EC is characterized by significant perturbations in important cellular metabolites. Metabolites accurately detected early-stage EC cases and EC overall which could lead to the development of non-invasive biomarkers for earlier detection of EC and for monitoring disease recurrence.
KeywordsEndometrial cancer Metabolomics Biomarker Nuclear magnetic resonance Mass spectrometry
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the IRB - I 03103 “RPCI Data Bank and BioRepository (DBBR)”. Samples and de-identified clinical data was distributed for analysis under RPCI IRB-approved protocol BDR 048414 “Metabolomic analysis of gynecologic and non-gynecologic cancers: a pilot study”.
Informed consent was obtained from all individual participants included in the study.
- Ambrosone, C. B., Nesline, M. K., & Davis, W. (2006). Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 15(9), 1575–1577. https://doi.org/10.1158/1055-9965.EPI-06-0628.CrossRefGoogle Scholar
- Antonsen, S. L., Hogdall, E., Christensen, I. J., Lydolph, M., Tabor, A., Loft Jakobsen, A., et al (2013). HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: A prospective multicenter study (ENDOMET). Acta Obstetricia et Gynecologica Scandinavica, 92(11), 1313–1322. https://doi.org/10.1111/aogs.12235.CrossRefPubMedGoogle Scholar
- Bahado-Singh, R. O., Akolekar, R., Mandal, R., Dong, E., Xia, J., Kruger, M., et al. (2012). Metabolomics and first-trimester prediction of early-onset preeclampsia. The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal of the European Association of Perinatal Medicine, The Federation of Asia and Oceania Perinatal Societies, The International Society of Perinatal Obstetricians, 25(10), 1840–1847. https://doi.org/10.3109/14767058.2012.680254.CrossRefGoogle Scholar
- Fujiwaki, R., Hata, K., Nakayama, K., Fukumoto, M., & Miyazaki, K. (2000). Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 18(23), 3946–3951.CrossRefGoogle Scholar
- Furberg, A. S., & Thune, I. (2003). Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. International Journal of Cancer, 104(6), 669–676. https://doi.org/10.1002/ijc.10974.CrossRefPubMedGoogle Scholar
- Garcia, E., Andrews, C., Hua, J., Kim, H. L., Sukumaran, D. K., Szyperski, T., et al. (2011). Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. Journal of Proteome Research, 10(4), 1765–1771. https://doi.org/10.1021/pr101050d.CrossRefPubMedPubMedCentralGoogle Scholar
- Gaudet, M. M., Falk, R. T., Stevens, R. D., Gunter, M. J., Bain, J. R., Pfeiffer, R. M., et al. (2012). Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study. The Journal of Clinical Endocrinology and Metabolism, 97(9), 3216–3223. https://doi.org/10.1210/jc.2012-1490.CrossRefPubMedPubMedCentralGoogle Scholar
- Liesenfeld, D. B., Habermann, N., Owen, R. W., Scalbert, A., & Ulrich, C. M. (2013). Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22(12), 2182–2201. https://doi.org/10.1158/1055-9965.EPI-13-0584.CrossRefGoogle Scholar
- Odunsi, K. (2007). Cancer diagnostics using 1H-NMR-based metabonomics. Ernst Schering Foundation Symposium Proceedings, 4, 205–226.Google Scholar
- Staff, A. C., Trovik, J., Eriksson, A. G., Wik, E., Wollert, K. C., Kempf, T., et al. (2011). Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17(14), 4825–4833. https://doi.org/10.1158/1078-0432.CCR-11-0715.CrossRefGoogle Scholar
- Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society: Series B (Methodological), 58(1), 267–288.Google Scholar
- Turkoglu, O., Zeb, A., Graham, S., Szyperski, T., Szender, J. B., Odunsi, K., et al. (2016). Metabolomics of biomarker discovery in ovarian cancer: A systematic review of the current literature. Metabolomics, 12(4), 60. https://doi.org/10.1007/s11306-016-0990-0.CrossRefPubMedPubMedCentralGoogle Scholar
- Urayama, S., Zou, W., Brooks, K., & Tolstikov, V. (2010). Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Communications in Mass Spectrometry: RCM, 24(5), 613–620. https://doi.org/10.1002/rcm.4420.CrossRefPubMedGoogle Scholar
- Vorkas, P. A., Shalhoub, J., Lewis, M. R., Spagou, K., Want, E. J., Nicholson, J. K., et al. (2016). Metabolic phenotypes of carotid atherosclerotic plaques relate to stroke risk: An exploratory study. European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery, 52(1), 5–10. https://doi.org/10.1016/j.ejvs.2016.01.022.CrossRefGoogle Scholar